NMS-0963 is a novel potent, selective and orally available Syk inhibitor with promising preclinical activity in diffuse large B-cell lymphoma

G. Saturno, M. Modugno, P. Orsini, G. Cervi, L. Buffa, I. Motto, N. Avanzi, M. Montemartini, F. Gasparri, G. Texido, A. Galvani, A. Isacchi
AACR Annual Meeting 2023; 2023 April 14-19; Orlando, FL.

–Abstract 4036
Cancer Res (2023) 83 (7_Supplement)